Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 152 | — | — | Mar 22, 2022 | Aug 31, 2027 | May 22, 2026 | 26 | United States, Australia +7 |
| Arm | Type | Description |
|---|---|---|
| Participants Receiving remzistotug Monotherapy (Arm A) | EXPERIMENTAL | - |
| Participants Receiving remzistotug Plus Dostarlimab (Arm B) | EXPERIMENTAL | - |
| Participants Receiving remzistotug Plus Dostarlimab Plus belrestotug (Arm C) | EXPERIMENTAL | - |
| Participants Receiving Dostarlimab Plus belrestotug (Arm D) | EXPERIMENTAL | - |
| Participants Receiving dostarlimab Plus belrestotug Plus remzistotug (Arm E) | EXPERIMENTAL | - |
| Participants Receiving dostarlimab Plus belrestotug Plus nelistotug (Arm F) | EXPERIMENTAL | - |
| China Cohort: Participants receiving dostarlimab (Arm G) | EXPERIMENTAL | - |
| Participants Receiving GSK5764227 Plus dostarlimab (Arm I) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Remzistotug | DRUG | Remzistotug will be administered. |
| Dostarlimab | DRUG | Dostarlimab will be administered. |
| Belrestotug | DRUG | Belrestotug will be administered. |
| Nelistotug | DRUG | Nelistotug will be administered. |
| GSK5764227 | DRUG | GSK5764227 will be administered. |
Inclusion criteria: * A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: * Is not a woman of childbearing potential (WOCBP) or * Is a WOCBP and using a contraceptive method that is highly effective with a...